Candel Therapeutics Inc (CADL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $486.37M
Last updated: Nov 17, 2026 at 11:04 AM ET
Candel Therapeutics Inc (CADL) Earnings: Report Dates and Results
Candel Therapeutics (CADL) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Candel Therapeutics reported EPS of -$0.28, above the -$0.30 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CADL has an expected report date of Mar 10, 2027.
Earnings History
Of the 21 quarters below that had an estimate, CADL beat 10 and missed 11. The widest gap in the table came in the quarter ended Dec 31, 2021, when EPS landed 196.88% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.28 | -$0.30 | -$0.33 - -$0.29 | +6.67% | Beat | N/A | 2 | 0 up, 1 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.35 | -$0.22 | -$0.26 - -$0.21 | -59.09% | Miss | N/A | 2 | 0 up, 0 down | Aug 13, 2026 | N/A |
| Mar 31, 2026 | -$0.14 | -$0.33 | -$0.52 - -$0.24 | +57.58% | Beat | N/A | 5 | 0 up, 3 down | May 14, 2026 | N/A |
| Dec 31, 2025 | -$0.29 | -$0.25 | -$0.25 - -$0.22 | -17.01% | Miss | N/A | 2 | 2 up, 0 down | Mar 12, 2026 | N/A |
| Sep 30, 2025 | -$0.23 | -$0.16 | -$0.21 - -$0.12 | -43.75% | Miss | N/A | 2 | 1 up, 0 down | Nov 13, 2025 | N/A |
| Jun 30, 2025 | -$0.20 | -$0.17 | -$0.18 - -$0.17 | -17.65% | Miss | N/A | 2 | 1 up, 0 down | Aug 14, 2025 | N/A |
| Mar 31, 2025 | -$0.14 | -$0.24 | -$0.24 - -$0.24 | +41.67% | Beat | N/A | 1 | 1 up, 0 down | May 13, 2025 | N/A |
| Dec 31, 2024 | -$0.40 | -$0.30 | N/A | -33.33% | Miss | N/A | N/A | N/A | Mar 13, 2025 | $1.00M |
| Sep 30, 2024 | -$0.33 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2024 | N/A |
| Jun 30, 2024 | -$0.74 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Aug 13, 2024 | N/A |
| Mar 31, 2024 | -$0.28 | -$0.28 | N/A | -0.57% | Miss | N/A | N/A | 0 up, 0 down | May 14, 2024 | N/A |
| Dec 31, 2023 | -$0.38 | -$0.16 | -$0.16 - -$0.16 | -137.50% | Miss | N/A | 1 | 0 up, 0 down | Mar 28, 2024 | $1.78M |
| Sep 30, 2023 | -$0.29 | -$0.19 | -$0.19 - -$0.19 | -52.63% | Miss | N/A | 1 | 0 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$0.33 | -$0.37 | -$0.37 - -$0.23 | +10.81% | Beat | N/A | 2 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$0.30 | -$0.35 | N/A | +14.29% | Beat | N/A | 2 | 1 up, 0 down | May 11, 2023 | N/A |
| Dec 31, 2022 | -$0.18 | -$0.31 | -$0.54 - -$0.16 | +41.94% | Beat | -158.1% | 3 | 0 up, 0 down | Mar 30, 2023 | $32000 |
| Sep 30, 2022 | -$0.31 | -$0.36 | -$0.53 - -$0.19 | +13.89% | Beat | N/A | 3 | 0 up, 0 down | Nov 10, 2022 | $31000 |
| Jun 30, 2022 | -$0.32 | -$0.43 | N/A | +25.58% | Beat | N/A | 2 | 0 up, 0 down | Aug 5, 2022 | $31000 |
| Mar 31, 2022 | -$0.32 | -$0.31 | -$0.42 - -$0.21 | -3.23% | Miss | N/A | 3 | 0 up, 0 down | May 12, 2022 | $31000 |
| Dec 31, 2021 | $0.31 | -$0.32 | -$0.49 - -$0.20 | +196.88% | Beat | N/A | 3 | 0 up, 0 down | Mar 29, 2022 | $32000 |
| Sep 30, 2021 | -$0.34 | -$0.29 | -$0.31 - -$0.27 | -17.24% | Miss | N/A | 2 | N/A | Nov 12, 2021 | $31000 |
| Jun 30, 2021 | -$0.31 | -$0.12 | -$0.12 - -$0.12 | -158.33% | Miss | N/A | 1 | N/A | Jul 28, 2021 | $31000 |
| Mar 31, 2021 | -$0.35 | -$0.35 | N/A | +0.74% | Beat | N/A | N/A | N/A | Jun 2, 2021 | $31000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.86, after -$1.75 the year before. It was -$0.69 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.86 | N/A |
| Dec 31, 2024 | -$1.75 | N/A |
| Dec 31, 2023 | -$1.30 | N/A |
| Dec 31, 2022 | -$1.13 | N/A |
| Dec 31, 2021 | -$0.69 | N/A |
Frequently Asked Questions About CADL
When is Candel Therapeutics's next earnings date?
Candel Therapeutics's next earnings report is expected for Mar 10, 2027.
Did CADL beat earnings estimates last quarter?
Yes. Candel Therapeutics reported EPS of -$0.28 for the quarter ended Sep 30, 2026, above the -$0.30 estimate, a 6.67% surprise.
What EPS do analysts expect from CADL next quarter?
The consensus EPS estimate for Candel Therapeutics for the quarter ending Dec 31, 2026 is -$0.38 from 12 analysts, with estimates from -$0.60 to -$0.08.
How often does CADL beat earnings estimates?
Candel Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -8.12%.
CADL pages: Overview, Earnings, Forecast, Financials, Competitors